Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. The Big Pharma is offering the California biotech up to $65 million in upfront, near ...

Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

Last week, US pharma giant Pfizer chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference ...

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.